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ABSTRACT
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved 
for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-
positive, metastatic breast cancer (mBC). The aim of this ‘field-practice’ study was 
to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous 
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INTRODUCTION
Trastuzumab, a humanized IgG1 monoclonal 
antibody, was the first targeted therapy against the human 
epidermal growth factor receptor 2 (HER2) showing 
clinical efficacy in patients with breast cancer [1]. Despite 
its efficacy, virtually all patients with metastatic breast 
cancer (mBC) will eventually develop disease progression 
to trastuzumab, and some early-stage patients will recur 
after adjuvant treatment, thus making de novo and 
acquired resistance a major clinical issue [2].
Therefore, a number of HER2-directed therapies 
have been developed with the aim to overcome resistance 
to trastuzumab, including lapatinib, pertuzumab, and ado-
trastuzumab emtansine (T-DM1). 
In particular, T-DM1 is an antibody-drug conjugate 
that combines trastuzumab and DM1 (also called 
emtansine), a derivative of the anti-microtubule agent 
maytansin, which is able to deliver highly effective 
chemotherapy to targeted cells sparing adverse effects [2, 
3]. The efficacy of T-DM1 in the second-line treatment 
of mBC has been shown in the pivotal, phase III open-
label EMILIA trial, in which this therapeutic strategy 
was compared with the combination of lapatinib and 
capecitabine [4]. With a median follow-up of 19 months, 
progression-free survival (PFS) was 9.6 months with 
T-DM1 and 6.4 months with lapatinib and capecitabine, 
respectively. Moreover, a prolonged overall survival 
(OS) was also observed in the T-DM1 group (30.9 vs. 
25.1 months). The most common grade (G) 3/4 adverse 
events (AEs) in the T-DM1 group were thrombocytopenia 
(12.9%) and elevated liver transaminases (7.2%), whereas 
in the control arm were hand foot syndrome (16.4%) and 
diarrhea (20.7%). Following the results of the EMILIA 
trial, T-DM1 was the first antibody-drug conjugated 
approved in cancer treatment, specifically for the therapy 
of mBC patients who had received trastuzumab and a 
taxane. In a subsequent phase III study, T-DM1 showed 
also efficacy as a sequential treatment after lapatinib and 
trastuzumab (TH3RESA trial) [5, 6].
However, populations included in pivotal trials are 
often not fully representative of patients encountered in 
‘field-practice’; in addition, well-conducted observational 
studies can complement information provided by clinical 
trials [7]. To our knowledge, ‘field-practice’ information 
on T-DM1 is scant [8] and no observational study has 
specifically investigated the activity of this drug according 
to a number of factors such as treatment line, prior 
lapatinib therapy and the location of metastatic sites.
This multicenter ‘field-practice’ study conducted 
in Italy, investigates the activity and safety of T-DM1, 
focusing on treatment line, previous lapatinib and pattern 
of metastasis.
RESULTS
Study population
Three hundred and three patients were overall 
enrolled from April 2012 to June 2016 (Table 1). 
Median age was 51 years (range 27-78). The majority of 
patients (n = 200; 66%) had an HER2 3+ tumor, as for 
immunohistochemical (IHC) evaluation. Two hundred 
and twenty-one (73%) presented visceral metastases. 
About half of the patients (49%) had received prior 
hormonal therapies and the majority of patients had 
undergone an anthracycline-based (96%) or a taxane-
based chemotherapy (98%). 
Sixty-nine patients (23%) had received one line 
of prior anti-HER2 treatment for metastatic disease, 84 
(27%) two lines, 39 (13%) three lines and 72 (24%) more 
than three lines of therapy.
Prior to T-DM1 administration, first- and second-
line anti HER2 treatments yielded an objective response 
rate (ORR) of 60.6% and 46.4%, respectively, and a 
median PFS of 12 months (range: 2-132) and 8 months 
(range: 1-82), respectively.
In total, 149 patients were previously treated with 
lapatinib: of these, 17 (11%) in first-line setting, 130 
(87%) as second-line treatment and 2 (1%) in further 
treatment lines (Table 1). 
lapatinib treatment and patterns of metastasis. Three hundred and three patients  with 
HER2-positive mBC who received T-DM1 were identified by reviewing the medical records of 
24 Italian Institutions. One hundred fourty-nine (49%) and 264 (87%) had received prior 
hormonal treatment and/or anti-HER2 targeted therapy, respectively. Particularly, 149 
patients had been previously treated with lapatinib. The objective response rate (ORR) was 
36.2%, and 44.5% when T-DM1 was administrated as second-line therapy. Considering 
only patients with liver metastases, the ORR was 44.4%. The median progression-free 
survival (PFS) was 7.0 months in the overall population, but it reached 9.0 and 12.0 months 
when TDM-1 was administered as second- and third-line treatment, respectively.
In conclusion, in this ‘real-word’ study evaluating the effects of T-DM1 in patients with 
HER2-positive mBC who progressed on prior anti-HER2 therapies, we observed a clinically-
relevant benefit in those who had received T-DM1 in early metastatic treatment-line and 
in subjects previously treated with lapatinib.
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Table 1: Baseline characteristics (n = 303)
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Response rate and clinical benefit
A median of 6 cycles (range 1-32) of T-DM1 were 
administered. Information on response rate was available 
for 282 patients (Table 2). ORR was 36.2% (102/282), 
with a total of 11 CRs (3.9%). When T-DM1 was 
administered in the second-line setting, the ORR increased 
to 44.5% (52/117), while it dropped to 24.2% (23/95) for 
treatment beyond third line. With respect to metastatic 
sites, the highest ORR was reported for liver lesions 
(44.4%; Supplementary Table S1). The disease control rate 
(DCR) was 63.8% (180/282). The overall clinical benefit 
rate (CBR) at 6 months was 53.7% (144/268); CBR was 
60.2% in the second-line setting, 54.7% in the third-line 
setting, and 44.2% beyond the third line.
We were interested in studying the response rate to 
T-DM1 administrated in patients whose last anti-HER2 
treatment before T-DM1 was lapatinib (Table 3). A total of 
116 patients received T-DM1 at progression of lapatinib. 
Figure 1: Progression-free survival in overall population treated with T-DM1. T-DM1 treatment median PFS = 7 months 
(95% CI: 5.8-8.2).
*IHC: immunoistochemistry; SISH/FISH: Silver in situ hybridization/Fluorescent in situ hybridization; °Previous hormonal 
treatments: tamoxifen, steroidal and no-steroidal aromatase inhibitors
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Figure 2: Progression-free survival according to T-DM1 treatment line. T-DM1 II line treatment median PFS = 9.0 months 
(95% CI: 6.4-11.6) T-DM1 III line treatment median PFS = 12.0 months (95% CI: 9.7-16.3) T-DM1 > III line treatment median PFS = 5.0 
months (95% CI: 4.0-5.9).
Figure 3: Progression-free survival according to metastatic sites. Median PFS of patients with visceral metastases = 9 months 
(95% CI: 6.2-11.8). Median PFS of patients without visceral metastases = 7.0 months (95% CI: 5.6-8.4).
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Ten out of the 117 patients (8.5%) who received T-DM1 
as second-line treatment had already received lapatinib in 
the first-line setting; among them, one resistant to lapatinib 
resulted partially responsive to T-DM1 treatment; of the 
remaining nine, 3 partially responded to T-DM1 after a 
stable disease during lapatinib and 6 maintained stable 
disease as best response. Similarly, among 41 patients who 
had received lapatinib as second-line therapy and T-DM1 
as third-line treatment, 11 (27%) responded to T-DM1, 
with 2 patients achieving a CR. Among 105 patients who 
received T-DM1 as fourth-line, 65 received lapatinib in 
third-line: 15 had progressed on lapatinib, of these, 4 
(27%) experienced a response to T-DM1; twenty-five 
patients showed stability to lapatinib as best response, and 
9 of them (36%) responded to T-DM1. The disease control 
rates of T-DM1 after lapatinib when given as second-line, 
third-line and fourth-line were 100%, 63% and 77%, 
respectively.
Thirty-four patients received pertuzumab as first-
line therapy and TDM1 as second-line treatment. Three 
out of 14 patients in progression with pertuzumab 
achieved stable disease with T-DM1; on the other hand, 
among 6 patients in stable disease with pertuzumab 
partially responded to T-DM1. 
Table 2: Response to T-DM1 
Tumor response I line n(%)(n=6)
II line n(%)
(n=117)
III line n(%)
(n=64)
>III line n(%)
(n=95)
Total n(%)
(n=282)
Complete Response 0 (0) 6 (5) 4 (6.3) 1 (1,1) 11 (3.9)
Partial Response 1 (16.7) 46 (39) 22 (34.4) 22 (23.1) 91 (32.3)
Overall Response rate 1 (16.7) 52 (44.4) 26 (40.6) 23 (24.2) 102 (36.2)
Stable Disease 5 (83.3) 28 (24) 15 (23.4) 30 (31.6) 78 (27.6)
Progression Disease 0 (0) 37 (32) 23 (35.9) 42 (44.2) 102 (36.2)
Clinical Benefit* - 60% 55% 44% 53.7%
*Clinical benefit at 6 months 
Table 3: Response to lapatinib and T-DM1 treatment (sequential therapy)
Treatment setting n. of patients
Treatment response (%)
PD SD PR CR
I line - lapatinib
10
1 (10) 9 (90) 0 0
II line - T-DM1 0 6(60) 4 (40) 0
                                DCR 100%
II line - lapatinib
41
14 (34) 15 (36.5) 12 (29) 2 (5)
III line - T-DM1 13 (32) 17 (41) 9 (22) 2 (5)
DCR 63%
III line - lapatinib
65
15 (23) 25 (38) 23 (35) 2 (3)
IV line - T-DM1 15 (23) 37 (57) 13 (20) 0
DCR 77%
CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease
DCR= disease control rate
Table 4: Adverse events (evaluable in 303 patients)
N (%)
Grade Neutropenia Anemia Thrombocytopenia Mucositis Diarrhea Transaminases Neuropathy Alopecia Asthenia
1 18 (6) 28 (9) 44 (14.5) 18 (6) 41 (13.5) 18 (6) 17 (6) 4 (1) 64 (21)
2 7 (2) 7 (2) 26 (8.5) 2 (0.7) 6 (2) 7 (2) 4 (1) 8 (3) 33 (11)
3 2 (0.7) 0 (0) 7 (2) 0 (0) 0 (0) 2 (0.7) 0 (0) 5 (2) 3 (1)
4 1 (0.3) 0 (0) 1 (0.3) 0 (0) 0 (0) 1 (0.3) 0 (0) 0 (0) 0 (0)
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Survival
In the overall population, at a median follow up of 
10.0 months, (95% CI: 5.8-8.2) (Figure 1). 
Median PFS was longer when treatment was 
administered at third line setting (12.0 months, 95% 
CI: 9.7-16.3, p = 0.001) compared with other treatment 
lines (9.0 months, 95% CI: 6.4-11.6, and 5 months, 95% 
CI: 4.0-5.9, in the second and beyond the third line of 
treatment, respectively) (Figure 2). 
In the overall population, at a median follow up of 
8.0 months, the median overall survival was not reached. 
The 2-year OS rate was 61%; no difference was seen 
according to line of T-DM1 therapy (second-line: 61%; 
third-line: 74%; > third-line: 52%). The 8 patients in 
which this treatment was administered in the first-line 
setting were all alive at the time of analysis. 
Comparison of median PFS between patients 
with and without visceral metastases did not reveal any 
significant difference, 9.0 months (95% CI: 6.2-11.8) 
and 7.0 months (95% CI: 5.6-8.4), respectively (p = 
0.16) (Figure 3). An analysis of PFS among patients with 
and without brain metastases showed the following: for 
patients without brain metastases the median PFS was 8 
months (95% CI: 5.7-10.3), and the PFS rate was 53% 
and 37% at 6 and 12 months, respectively. For those with 
brain metastases the median PFS was 7 months (95% CI: 
5.4-8.6) and the PFS rate was 51% and 22% at 6 and 12 
months, respectively (p = 0.059).
Safety
All 303 patients were evaluable for safety. Table 
4 reports the incidence of adverse events (AEs) in all 
patients treated with T-DM1. The most common AEs 
were: asthenia (100/303, 33%), thrombocytopenia 
(78/303, 25.7%) and increased transaminases (28/303, 
9.2%). The majority of AEs were of grade 1 or 2; only 19 
grade 3 AEs (alopecia, n = 5; thrombocytopenia, n = 7; 
neutropenia, n = 2; increased transaminases, n = 5) and 3 
G4 AEs (thrombocytopenia, neutropenia and transaminase 
increasing) were reported.
In total, 41 (13.5%) patients had dose reduction after 
a median of 5 cycles (range 3-6) mainly for grade 3 and 
4 thrombocytopenia, grade 4 neutropenia and increase 
in transaminases. Only 3 (0.9%) patients required the 
administration of growth factors for a total of 13 cycles 
(0.5%).
DISCUSSION
To our knowledge, this is the first large ‘field-
practice’ study to investigate the activity and safety of 
T-DM1 in an unselected, real-world population of mBC 
patients previously treated. In particular, we focused our 
analysis on the effects of T-DM1 according to the line 
of treatment, a previous lapatinib administration and the 
presence of visceral metastases. 
Although we analyzed an unselected, heavily pre-
treated population of mBC patients, our data are fairly 
consistent with those reported in T-DM1 clinical trials. 
In the second-line setting, the observed median PFS (9.0 
months) and the ORR (44.4%) in our population are 
similar with the data reported in the pivotal EMILIA study 
(9.6 months and 43.6%, respectively) [4]. Noteworthy, in 
our retrospective analysis, the median PFS of patients 
treated with T-DM1 in third line setting resulted even 
higher (12 months). In the recently published, phase 
III MARIANNE study, 1095 patients with previously 
untreated HER2-positive mBC were randomly assigned to 
trastuzumab plus taxane (as control), T-DM1 plus placebo, 
or T-DM1 plus pertuzumab at standard doses [9]. In this 
study, T-DM1 (alone or in combination with pertuzumab) 
administrated in the first-line setting, failed to show longer 
PFS when compared with the control arm. It must be noted 
that the population enrolled in the MARIANNE trial does 
not represent the majority of mBC patients encountered 
in clinical practice. However, a stratification analysis 
revealed a trend for an increased T-DM1 efficacy in 
those patients who had received HER2-directed therapy 
or taxanes in the early breast cancer setting. Consistently 
with the results of the MARIANNE study, in our study 
T-DM1 treatment seemed to be associated with the best 
outcomes when administrated as third line treatment, in 
heavily pretreated mBC patients. These findings may pave 
the way for further studies aimed at identifying predictors 
of response to T-DM1. 
Compared with the subgroup of patients exposed to 
T-DM1 in the second-line setting, most of mBC patients 
treated with T-DM1 as third line had previously received 
lapatinib (8.5% vs. 56%, respectively). Therefore, we 
preliminary speculate that the surprisingly longer PFS 
of T-DM1-treated patients in third-line setting could 
be associated with prior lapatinib administration. This 
observation is consistent with the in vitro evidence 
reported by Scaltriti et al [8], suggesting that lapatinib 
may revert resistance to trastuzumab by yielding the 
accumulation of HER2 receptors on the surface of breast 
cancer cell. Although with all the limitations of any 
retrospective analysis, this finding may suggest, for the 
first time to our knowledge, more favorable outcomes in 
patients with prior lapatinib administration and therefore 
help identifying patients who are more likely to benefit 
from T-DM1 therapy. Prospective studies on this issue 
are lacking, and are needed to further investigate this 
preliminary finding. 
Overall, T-DM1 was well tolerated: the incidence 
rates of AEs of grade 3 or above was low, with only few 
patients (13.5%) needing dose reduction. This finding is 
in line with the recent retrospective ‘field-practice’ study 
by Dzimitrowicz et al [7], which reported a 10% incidence 
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of discontinuation for adverse events. The same study 
examined the T-DM1 activity as second or further line 
treatment on mBC patients who had previously received 
pertuzumab: patients mainly received T-DM1 as fourth-
line therapy or subsequent (48%), only 32% of these 
patients were treated with T-DM1 in the first or second-
line setting. Differently, in our population, 34.7% received 
the drug in fourth line setting or later and 41.2% of 
patients received T-DM1 treatment in first or second line 
setting instead. Noteworthy, in the present paper we did 
not report any subgroup analysis of T-DM1 activity after 
treatment with pertuzumab/trastuzumab/taxane. However, 
this analysis will be subject of a dedicated manuscript, 
which is now ready for submission.
Over the latest years, observational studies are being 
increasingly used to evaluate the activity of treatments 
in real-world populations, to fill in data gaps from 
randomized studies or when randomized studies cannot 
be conducted [10]. In addition, observational studies can 
be done with a relatively low cost and often enrolling an 
unselected population of patients usually not included in 
clinical studies [10]. However, careful attention must be 
paid to the observational study design in order to minimize 
the risk of selection biases [10].
Limitations of our investigation include those shared 
by all ‘field-practice’ studies such as poor reporting, 
different clinical approaches between participating 
Centers and lack of external validation. These limitations 
could introduce potential bias in the outcome assessment. 
However, data provided from ‘real world’ data are crucial 
for a more comprehensive evaluation of the T-DM1 
efficacy.
In conclusion, this multicenter, observational study 
provides ‘real life’ information on the efficacy and safety 
of T-DM1 in patients with metastatic HER2-positive 
breast cancer who experienced progression on prior taxane 
and HER2-neu inhibition approaches. In particular, we 
observed a potential clinically relevant beneficial effect in 
patients who received T-DM1 in early lines of treatment 
and in patients previously treated with lapatinib. To the 
best of our knowledge this is the first study investigating 
the activity of T-DM1 treatment in clinical practice on 
mBC patients who had previously received lapatinib. 
Additional prospective observational studies are needed 
to further investigate these findings. 
PATIENTS AND METHODS
The medical records of twenty-four different Italian 
Institutions were reviewed to identify HER2 positive 
mBC patients who had been treated with T-DM1. Eligible 
patients were required to have a diagnosis of HER2 
positive tumor. HER2 positivity was determined locally, 
and defined as 3+ immunohistochemical (IHC) staining 
(HercepTest; Dako A/S, Glostrup, Denmark) or 2+ IHC 
staining and HER2/Vep17 Ratio > 2 at fluorescence in 
situ hybridization (FISH) (PathVision HER2 DNA probe 
kit; Vysis Inc., Downers Grove, IL). Only patients with 
measurable and/or evaluable disease were included.
No restriction was made on the basis of previous 
lines of therapies received for metastatic disease. 
Progressive and/or recurrent disease prior T-DM1 
initiation had to be documented in all cases. 
Patients who had discontinued HER2-targeted 
therapies for any cause before the progression of disease 
were excluded from this analysis. 
In Italy, T-DM1 is reimbursed by the Healthcare 
System; prescriptions are made through a central 
electronic registry of the Agenzia Italiana del Farmaco 
(AIFA). This registry mandates tumor restaging every 3 
cycles (9 weeks), otherwise not permitting further drug 
prescriptions. Therefore, all patients in this series had 
similar restaging timing. 
For the purpose of this analysis, an evaluation of the 
patient’s disease based on the Response Evaluation Criteria 
in Solid Tumors (RECIST) [11] was requested. Overall 
response rate (ORR) was defined as the proportion of 
patients achieving complete (CR) or partial remission (PR) 
among those with measurable disease. Disease control 
rate (DCR) was defined as the addition of complete, 
partial responses and stability of disease. Clinical benefit 
rate (CBR) was considered as the proportion of patients 
with CR, PR or a stable disease (SD) lasting more than 6 
months.
Progression free survival (PFS) was considered as 
the period elapsing from the initiation of T-DM1 treatment 
to the date of the first evidence of progressive disease or 
death due to any cause, whichever occurred first. Survival 
curves were estimated by the Kaplan-Meier method and 
differences between curves were evaluated by the log-
rank test. For overall survival (OS), patients alive were 
censored at the date of the last follow-up. 
Toxicity was assessed according to the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events (version 4.2) grade scaling. 
Abbreviations
mBC = metastatic breast cancer; T-DM1 = ado-
trastuzumab emtansine; HER2 = epidermal growth factor 
receptor 2-positive; IHC = immunohistochemical; FISH = 
fluorescence in situ hybridization; AIFA = Agenzia Italiana 
del Farmaco; RECIST = Response Evaluation Criteria 
in Solid Tumors; PFS = progression-free survival; OS = 
overall survival; AEs = adverse events; G = grade; PD = 
progressive disease; SD = stable disease; CR = complete 
remission; PR = partial remission; ORR = objective 
response rate; DCR = disease control rate; CBR = clinical 
benefit rate. 
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